Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, ...
It often begins with a diagnosis; just a name on paper, something clinical and distant. But behind that name can be stories ...
Changes within the central nervous system, including the brain and spinal cord, can be a key reason for pain in people with ...
The emergence of neuropsychiatric disorders, conditions that affect various brain functions and behaviors, is known to be ...
Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month, with a string of appointments bringing deep commercial, scientific, and regulatory expertise to ...
The funds will support further development of Nervonik’s sensing technology and commercialisation of its PNS platform.